BDBM455297 US10730874, Compound TABLE II.2::US11180484, Example 77::US11352356, Table II.2

SMILES COCc1nn(Cc2ccc(nc2)N2CCCC2)cc1C(=O)NCc1c(F)c(OC)ccc1-n1cnnn1

InChI Key InChIKey=DGIRMJAUTLUPMU-UHFFFAOYSA-N

Data  1 KI  4 IC50  2 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 455297   

TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM455297(US10730874, Compound TABLE II.2 | US11180484, Exam...)
Affinity DataKi:  0.170nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 18...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM455297(US10730874, Compound TABLE II.2 | US11180484, Exam...)
Affinity DataIC50:  1.40nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKallikrein-1(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM455297(US10730874, Compound TABLE II.2 | US11180484, Exam...)
Affinity DataIC50: >4.00E+4nMAssay Description:KLK1 inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM455297(US10730874, Compound TABLE II.2 | US11180484, Exam...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XII(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM455297(US10730874, Compound TABLE II.2 | US11180484, Exam...)
Affinity DataIC50: >4.00E+4nMAssay Description:Factor XIIa inhibitory activity in vitro was determined using standard published methods (see e.g. Shori et al., Biochem. Pharmacol., 1992, 43, 1209;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM455297(US10730874, Compound TABLE II.2 | US11180484, Exam...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM455297(US10730874, Compound TABLE II.2 | US11180484, Exam...)
Affinity DataIC50:  235nMAssay Description:FXIa inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent